Perspective Therapeutics, Inc. (CATX) Income Statement
CATX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCATX revenue and net income
Where CATX's revenue goes
2025Each bar shows an amount and its share of revenue. CATX kept −11,665.3% of revenue as net income.
CATX profit margins
CATX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −39.2% | −50.1% | −39.4% | −21.3% |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CATX quarterly EPS vs estimates
Perspective Therapeutics beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.24).
CATX income statement
| 2025 | 2024 | 2023 | 2023 | 2022 | 2022 | 2021 | 2021 | 2020 | 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $884,000 | $1.5M | $1.4M | $7.1M | $5.4M | $10.8M | $10.8M | $10.1M | $10.1M | $9.7M |
| Cost of revenue | $3.3M | $2.3M | $0 | $5.5M | $3.0M | $6.2M | $6.2M | $4.9M | $4.9M | $4.6M |
| Gross profit | −$2.4M | −$852,000 | $1.4M | $1.6M | $2.4M | $4.6M | $4.6M | $5.1M | $5.1M | $5.1M |
| Research & development | $84.2M | $39.3M | $21.3M | $2.6M | $1.8M | $2.6M | $2.6M | $1.4M | $1.4M | $1.1M |
| Sales, general & admin | $30.2M | $26.6M | $21.1M | $14.1M | $9.4M | $9.4M | $9.4M | $7.1M | $7.1M | $7.5M |
| Total operating expenses | $113.6M | $65.9M | $42.4M | $17.4M | $11.5M | $12.0M | $18.2M | $8.6M | $8.6M | $8.6M |
| Operating income | −$113.6M | −$66.8M | −$40.9M | −$15.2M | −$9.1M | −$7.4M | −$7.4M | −$3.4M | −$3.4M | −$3.5M |
| Interest income | $8.1M | $10.5M | $934,000 | — | — | $119,000 | $119,000 | $59,000 | $59,000 | $30,000 |
| Interest expense | $376,000 | $48,000 | $84,000 | — | $119,000 | $119,000 | — | $50,000 | — | $30,000 |
| Income before taxes | −$104.4M | −$80.4M | −$40.1M | −$14.7M | −$8.5M | −$7.3M | −$7.3M | −$3.4M | −$3.4M | −$3.4M |
| Income taxes | −$793,000 | −$2.1M | −$2.7M | — | −$119,000 | −$119,000 | — | −$199,000 | −$199,000 | −$177,000 |
| Net income | −$103.1M | −$79.3M | −$46.5M | −$14.7M | −$10.8M | −$7.2M | −$7.3M | −$3.2M | −$3.2M | −$3.3M |
| EBITDA | −$100.8M | −$64.5M | −$40.0M | −$14.8M | −$8.5M | −$7.1M | −$7.1M | −$3.4M | −$3.4M | −$3.3M |
| EPS (diluted) | −$1.41 | −$1.16 | −$0.90 | −$0.22 | −$0.16 | −$0.26 | −$0.41 | −$0.23 | −$0.32 | −$0.48 |
| Gross margin | −267.8% | −58.6% | 100.0% | 23.0% | 43.7% | 42.8% | 42.8% | 50.9% | 50.9% | 52.9% |
| Operating margin | −12,846.6% | −4,594.0% | −2,855.0% | −213.7% | −168.1% | −68.5% | −68.5% | −34.2% | −34.2% | −35.9% |
| Net margin | −11,665.3% | −5,452.5% | −3,243.2% | −206.5% | −198.7% | −66.3% | −67.4% | −31.7% | −31.7% | −33.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $81,000 | $76,000 | $43,000 | $209,000 | $290,000 | $369,000 | $234,000 | $369,000 | $325,000 | $276,000 | $0 | $2.1M |
| Cost of revenue | $1.1M | $1.1M | $1.0M | $775,000 | $733,000 | $669,000 | $709,000 | $669,000 | $356,000 | $209,000 | $5.2M | $1.8M |
| Gross profit | $81,000 | −$1.1M | −$968,000 | −$566,000 | −$443,000 | −$300,000 | −$475,000 | −$300,000 | −$31,000 | $67,000 | −$5.2M | $248,000 |
| Research & development | $21.5M | $20.2M | $32.9M | $20.3M | $12.2M | $11.4M | $12.9M | $12.0M | $7.5M | $5.4M | $6.1M | $5.7M |
| Sales, general & admin | $7.8M | $7.0M | $7.0M | $7.7M | $7.7M | $7.8M | $8.2M | $7.0M | $5.5M | $5.9M | $4.3M | $5.6M |
| Total operating expenses | $29.3M | $27.2M | $39.8M | $27.3M | $23.6M | $18.3M | $45.0M | $18.6M | $13.0M | $9.8M | $2.6M | $11.6M |
| Operating income | −$29.3M | −$28.3M | −$39.8M | −$27.9M | −$24.0M | −$18.6M | −$45.0M | −$18.6M | −$13.0M | −$9.8M | −$7.8M | −$11.4M |
| Interest income | $2.3M | $2.2M | $1.6M | $2.0M | $2.2M | $2.4M | $2.6M | $3.6M | $3.1M | $1.2M | $62,000 | $204,000 |
| Interest expense | $71,000 | $105,000 | $64,000 | $65,000 | $119,000 | $69,000 | $73,000 | $69,000 | $29,000 | $14,000 | $24,000 | $28,000 |
| Income before taxes | −$26.8M | −$26.2M | −$38.3M | −$26.0M | −$22.0M | −$15.1M | −$42.3M | −$15.1M | −$11.8M | −$9.6M | −$8.9M | −$11.1M |
| Income taxes | $196,000 | — | −$793,000 | — | −$2.1M | — | −$2.1M | — | −$61,000 | — | $7.8M | $278,000 |
| Net income | −$26.8M | −$26.2M | −$37.5M | −$26.0M | −$21.5M | −$15.1M | −$40.2M | −$15.1M | −$12.3M | −$10.4M | −$24.7M | −$11.1M |
| EBITDA | −$25.6M | −$27.2M | −$37.2M | −$25.1M | −$21.1M | −$18.0M | −$41.6M | −$14.4M | −$12.6M | −$9.5M | −$8.6M | −$10.8M |
| EPS (diluted) | −$0.22 | −$0.25 | −$0.51 | −$0.35 | −$0.30 | −$0.25 | −$0.57 | −$0.21 | −$0.18 | −$0.20 | −$0.09 | −$0.40 |
| Gross margin | 100.0% | −1,381.6% | −2,251.2% | −270.8% | −152.8% | −81.3% | −203.0% | −81.3% | −9.5% | 24.3% | — | 11.9% |
| Operating margin | −36,121.0% | −37,211.8% | −92,632.6% | −13,330.6% | −8,289.3% | −5,049.9% | −19,223.9% | −5,049.9% | −4,001.5% | −3,532.6% | — | −545.5% |
| Net margin | −33,069.1% | −34,459.2% | −87,186.0% | −12,425.4% | −7,408.6% | −4,098.1% | −17,166.2% | −4,098.1% | −3,779.7% | −3,752.2% | — | −531.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CATX's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CATX financial results
In fiscal year 2025 (ended December 31, 2025), Perspective Therapeutics reported revenue of $0.9 million, down 39.2% from the year before. It had a net loss of $103.1 million, a net profit margin of −11,665.3%. Diluted earnings per share came to −$1.41. Over five years revenue grew at an average rate of −39.4% a year.
See the CATX stock overview for the latest quote and news, or the CATX chart for price history and technical indicators.
CATX income statement FAQ
What is Perspective Therapeutics's annual revenue?
Perspective Therapeutics reported total revenue of $0.9 million for fiscal year 2025, which ended on December 31, 2025. That was down 39.2% from $1.5 million the previous year.
Is Perspective Therapeutics profitable?
No. Perspective Therapeutics reported a net loss of $103.1 million in fiscal 2025, a net profit margin of −11,665.3%; its operating margin was −12,846.6%.
What is Perspective Therapeutics's gross margin?
Perspective Therapeutics's gross margin was −267.8% in fiscal 2025: for every $100 of revenue, Perspective Therapeutics kept $-268 after the direct cost of its products and services.
How much does Perspective Therapeutics spend on research and development?
Perspective Therapeutics spent $84.2 million on research and development in fiscal 2025, 9,526.6% of revenue.
How fast is Perspective Therapeutics growing?
Revenue grew −39.4% a year on average over the last five fiscal years, from $10.8 million to $0.9 million.
What are Perspective Therapeutics's earnings per share?
Perspective Therapeutics earned $-1.41 per diluted share in fiscal 2025, compared with $-1.16 a year earlier.
When will Perspective Therapeutics report its next earnings?
Perspective Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes.
When does Perspective Therapeutics's fiscal year end?
Perspective Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.